N/A N=23 Treatment of Keratosis Pilaris With 810 nm Diode Laser
Keratosis Pilaris (KP)
Primary: Difference in Disease Severity Scores — 4; 3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer
Breast Carcinoma · Radiation-Induced Dermatitis
Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
N/A N=25 KeraStat(R) Cream for Radiation Dermatitis
Radiation Dermatitis
Primary: Radiation Therapy Oncology Group Skin Toxicity Scoring — 0.00; 0.00; 0.09; 0.15 score on a scale
Phase 2 N=168 Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Actinic Keratosis
Primary: Percentage of Participants With Complete Response of Actinic Keratosis — 43; 32 percentage of participants
N/A N=58 Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
Lesion Skin · Seborrheic Keratosis
Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance
Phase 3 N=351 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
Actinic Keratosis
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 13; 54 percentage of participants — p=<0.0001
Phase 2 N=33 Study of SOR007 Ointment for Actinic Keratosis
Actinic Keratosis
Primary: Number of Participants With Treatment Emergent Adverse Events — 2; 1; 3; 1 Participants
N/A N=110 Skin Prick Test of KeraStat® Cream
Hypersensitivity
Primary: Reaction to Test Article — 0; 0.32; 0.23; 6.73 mm
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
Phase 3 N=351 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
Actinic Keratoses
Primary: Percentage of Participants With Complete (100%) Clearance of Actinic Keratosis (AK) Lesions — 5; 44 percentage of participants — p=<0.0001
Phase 3 N=490 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AK Lesions — 55; 41; 9 participants
Phase 2 N=24 Effects of PRK 124 Lotion in Acne Rosacea
Acne Rosacea
Primary: Erythema Severity — 44.53 Erythema percent improvement
Phase 3 N=60 Cryosurgery and Cream Combination for Actinic Keratosis
Actinic Keratosis
Primary: Number Participants With 100% Clearance — 12; 13 Participants
Phase 3 N=479 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
Actinic Keratoses
Primary: Number of Participants With Complete Clearance of AK Lesions — 57; 49; 10 participants
Phase 2 N=100 ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
Actinic Keratosis
Primary: Treatment Success at End of Study Visit — 66.7; 65.2; 76.0; 66.7 percentage of participants — p=0.799
Phase 2 N=16 A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
Actinic Keratosis
Primary: Maximum Observed Concentration (Cmax) for Ingenol Mebutate and Its Two Acyl Isomers (PEP015 and PEP025) Levels — NA; NA ng/mL
N/A N=20 Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
Actinic Keratoses
Primary: Efficacy of Tixel for Treatment of Actinic Keratosis — -90.4 percentage change
Phase 4 N=551 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Keratosis
Primary: Number of Participants Who Experienced an Adverse Event — 472 participants
Phase 2 N=83 Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Complete Clearance Rate — 7; 9 Participants
Phase 2 N=165 The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
Actinic Keratoses
Primary: Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance. — 22; 17; 19; 25 participants — p=0.60
N/A N=28 Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy
Head and Neck Cancer · Radiation Dermatitis
Primary: Completion Rate of Use of KeraStat Cream — 10; 7 Participants
Phase 3 N=26 Actinic Keratoses Treatment With Metvix® in Combination With Light
Actinic Keratoses
Primary: Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12 — 19.6; 20.0 number of lesions — p=0.8460
Phase 3 N=450 A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
Seborrheic Keratosis
Primary: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment — 9; 0 Participants
Phase 3 N=519 To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
Actinic Keratosis
Primary: Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions as Determined by Visual Inspection of the Investigator — 81; 76; 10 Participants
Phase 2 N=21 Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Actinic Keratosis
Primary: Number of Responders — 19 Participants
Phase 2 N=83 Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses
Precancerous Condition
Primary: Change in Histopathology Score of Sun Damaged Skin by Treatment Group — 0.4; -0.1; 0.1 units on a scale — p=0.10
Phase 3 N=255 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Actinic Keratoses
Primary: Patients With Complete Clearance of Actinic Keratosis (AKs) — 35; 6 Participants — p=<0.0001
Phase 3 N=203 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Actinic Keratoses
Primary: Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions — 42; 5 participants — p=0.001
Phase 3 N=450 Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AKs 8 Weeks After Randomisation — 43; 9; 25; 5 participants — p=0.001